Bausch + Lomb has revealed that its subsidiary has completed the acquisition of Elios Vision, a pioneer in minimally invasive glaucoma surgery (MIGS) techniques. The Elios technique utilizes an excimer laser during cataract surgeries to manage glaucoma without requiring any implants. According to Bausch + Lomb, this acquisition boosts their portfolio of glaucoma solutions, which already includes a range of both pharmaceutical and surgical treatments.
MIGS is renowned for providing a secure and effective solution to reducing intraocular pressure, boasting quicker recovery times compared to other surgical methods for glaucoma, as stated in a press release. The Elios procedure stands out for its tissue-conserving, precision-focused, non-thermal laser technology, with a high potential for widespread adoption for glaucoma care. While the technology holds the CE mark in Europe, the company is actively seeking approval from the FDA.
Elliot Friedman, former Chairman and CEO of Elios, noted that the synergy between cataract and glaucoma treatment could become the prevailing standard of care. Friedman believes that Bausch + Lomb’s expansive global reach significantly enhances the prospects of achieving this aim.
Luc Bonnefoy, President of the Surgical Division at Bausch + Lomb, stated, “Today’s announcement is a testament to our dedication to investing in intelligent, cutting-edge technologies that empower eye care providers to better serve the diverse needs of their patients.” He added that the ELIOS system provides a unique strategy for treating glaucoma, a condition projected to rise by 47% in prevalence from 2020 to 2040.”